Therapeutic agent

Rituximab

ModerateEvidence level
5Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Moderate
Mechanism
Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General
Safety
Infusion reactions, serious infections (including PML risk), hepatitis B reactivation, hypogammaglobulinemia. Requires specialist oversight, screening, monitoring.
Dosing
Typical rheumatology regimens 1000 mg IV x2 (2 weeks apart) or 375 mg/m² weekly x4; ME/CFS trials used similar; repeat as needed.
Anti-CD20 studied in ME/CFS (mixed prior). Several trials. Serious infection risk. Specialist use only for clear autoimmune subsets. 5 trial associations.

Clinical Trials

5 trial(s) registered

NCT IDTitlePhaseStatus
NCT06952413Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)Phase 2Recruiting
NCT01156922B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue SyndromePhase 2Terminated
NCT02229942B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.Phase 3Completed
NCT00848692Drug Intervention in Chronic Fatigue SyndromePhase 2Completed
NCT01156909B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue SyndromePhase 2Completed

Key Studies / References

  • See linked studies